Fig. 1: Survival and clinical score outcomes. | Nature Communications

Fig. 1: Survival and clinical score outcomes.

From: Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

Fig. 1

a Kaplan-Meier survival curves of vaccinated and treated animals. Animals were vaccinated/treated with rVSV-ZEBOV and/or MIL77 at the indicated day pre/post infection. n = 5 for all groups except experimental control (n = 1). Historical control rhesus macaques infected with EBOV-Kikwit were included for statistical comparisons (n = 12). Significance was measured using the log-rank (Mantel–Cox) test. Colored asterisks denote statistical significance to the same colored group. All p-values reported are two-tailed. p = 0.0253 for rVSV-ZEBOV + MIL77 vs. experimental control cohort; p = 0.0486 for rVSV-ZEBOV + MIL77 vs. rVSV-ZEBOV cohort; p = 0.0003 for rVSV-ZEBOV + MIL77 vs. Historical Control cohort; p = 0.0072 for rVSV-ZEBOV vs. Historical Control cohort; p = 0.0009 for MIL77 vs. Historical Control cohort; all other comparisons were statistically insignificant. Significance is graphically tiered as following: * = <0.05, ** = <0.005, and *** = <0.0005. Arrows denote color-coded cohort. Asterisk indicates day of challenge (day 0). b–d Clinical illness scores for rVSV-ZEBOV + MIL77 (b), rVSV-ZEBOV (c), and MIL77 (d) treated rhesus macaques. For each panel, dashed lines indicate temperature (left y-axis) and solid lines indicate clinical score (right y-axis).

Back to article page